Discovery and development of SQ109: A new antitubercular drug with a novel mechanism of action

Future Microbiology

Volumn 7, Issue 7, 2012, Pages 823-837

  Sacksteder, Katherine A ^a   Protopopova, Marina ^a   Barry, Clifton E ^b   Andries, Koen ^c   Nacy, Carol A ^a  

^a SEQUELLA INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

antitubercular agent; clinical trial; drug discovery; drug resistance; MDR TB; pharmacology; tuberculosis; XDR TB

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ADAMANTANE; AZD 5847; BEDAQUILINE; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PLACEBO; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ANAEROBIC INFECTION; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; COLONY FORMING UNIT; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SCREENING; DRUG TISSUE LEVEL; EYE TOXICITY; GRAM POSITIVE INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MORBIDITY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS; VOMITING;

ADAMANTANE; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHYLENEDIAMINES; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84864332596     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.56     Document Type: Review

References (80)

1. Stevenson CR, Forouhi NG, Roglic G et al. Diabetes and tuberculosis: The impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7, 234 (2007).
2. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163(9), 1009-1021 (2003). (Pubitemid 36548927)
3. Nolan CM. Beyond directly observed therapy for tuberculosis. Chest 111(5), 1151-1153 (1997). (Pubitemid 27200060)
4. Castelnuovo B. A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in sub Saharan Africa. Afr. Health Sci. 10(4), 320-324 (2010).
5. Vieira AA, Ribeiro SA. Compliance with tuberculosis treatment after the implementation of the directly observed treatment, short-course strategy in the city of Carapicuiba, Brazil. J. Bras. Pneumol. 37(2), 223-231 (2011).
6. Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N. Engl. J. Med. 330(24), 1703-1709 (1994).
7. O'Brien JK, Sandman LA, Kreiswirth BN, Rom WN, Schluger NW. DNA fingerprints from Mycobacterium tuberculosis isolates of patients confined for therapy noncompliance show frequent clustering. Chest 112(2), 387-392 (1997). (Pubitemid 27349428)
8. Coker RJ. Public health impact of detention of individuals with tuberculosis: Systematic literature review. Public Health 117(4), 281-287 (2003). (Pubitemid 36806092)
9. Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 330(17), 1179-1184 (1994). (Pubitemid 24121986)
10. Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect. Dis. 9(3), 153-161 (2009).
11. Zumla A, Abubakar I, Raviglione M et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J. Infect. Dis. 205(Suppl. 2), S228-S240 (2012).
12. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis. Lancet 375(9728), 1830-1843 (2010).
13. Sotgiu G, Ferrara G, Matteelli A et al. Epidemiology and clinical management of XDR-TB: A systematic review by TBNET. Eur. Respir. J. 33(4), 871-881 (2009).
14. Friedland G. Tuberculosis, drug resistance, and HIV/AIDS: A triple threat. Curr. Infect. Dis. Rep. 9(3), 252-261 (2007). (Pubitemid 46736263)
15. Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis: The perfect storm. J. Infect. Dis. 196(Suppl. 1), S86-S107 (2007). (Pubitemid 47206088)
16. Farley JE, Ram M, Pan W et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One 6(7), e20436 (2011).
17. Ginsberg AM. Drugs in development for tuberculosis. Drugs 70(17), 2201-2214 (2010).
18. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr. Med. Chem. 15(19), 1956-1967 (2008).
19. Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr. HIV/AIDS Rep. 7(3), 143-151 (2010).
20. Dover LG, Coxon GD. Current status and research strategies in tuberculosis drug development. J. Med. Chem. 54(18), 6157-6165 (2011).
21. Sala C, Hartkoorn RC. Tuberculosis drugs: New candidates and how to find more. Future Microbiol. 6(6), 617-633 (2011).
22. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008).
23. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360(23), 2397-2405 (2009).
24. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(4), 1797-1809 (2012).
25. Grzegorzewicz AE, Pham H, Gundi VA et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8(4), 334-341 (2012).
26. Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann. NY Acad. Sci. 1222, 49-54 (2011).
27. Villar M, Sotgiu G, D'Ambrosio L et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J. 38(3), 730-733 (2011).
28. Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34(2), 387-393 (2009).
29. Von Der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - A report of ten cases. J. Infect. 52(2), 92-96 (2006). (Pubitemid 43137390)
30. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 50(1), 49-55 (2010).
31. Dietze R, Hadad DJ, McGee B et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 178(11), 1180-1185 (2008).
32. Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. 50(Suppl. 1), S16-S23 (2010).
33. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43(5), 1285-1288 (1999). (Pubitemid 29214765)
34. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13(11), 908-914 (1994).
35. Paramasivan CN, Kubendiran G, Herbert D. Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. Indian J. Med. Res. 108, 115-119 (1998). (Pubitemid 28479412)
36. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198(2), 275-283 (2008). (Pubitemid 352019294)
37. Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2(9), 736-742 (1998). (Pubitemid 28429724)
38. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46(4), 1022-1025 (2002). (Pubitemid 34260345)
39. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15(7), 949-954 (2011).
40. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54(8), 3402-3407 (2010).
41. Barbachyn MR, Hutchinson DK, Brickner SJ et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. 39(3), 680-685 (1996). (Pubitemid 26069690)
42. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43(5), 1189-1191 (1999). (Pubitemid 29214745)
43. Shaw KJ, Barbachyn MR. The oxazolidinones: Past, present, and future. Ann. NY Acad. Sci. 1241(1), 48-70 (2011).
44. Wallis RS, Jakubiec W, Kumar V et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55(2), 567-574 (2011).
45. Wallis RS, Jakubiec WM, Kumar V et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202(5), 745-751 (2010).
46. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE 3rd. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5(2), 172-187 (2003). (Pubitemid 37123511)
47. Desimoni G. Preliminary observations of ethambutol in pulmonary tuberculosis. Ann. NY Acad. Sci. 135(2), 846-848 (1966).
48. Donomae I, Yamamoto K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann. NY Acad. Sci. 135(2), 849-881 (1966).
49. Zhu M, Burman WJ, Starke JR et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8(11), 1360-1367 (2004). (Pubitemid 39611583)
50. Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182(7), 1802-1811 (2000). (Pubitemid 30165365)
51. Bogatcheva E, Hanrahan C, Nikonenko B et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg. Med. Chem. Lett. 21(18), 5353-5357 (2011).
52. Bogatcheva E, Hanrahan C, Nikonenko B et al. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J. Med. Chem. 49(11), 3045-3048 (2006). (Pubitemid 43830500)
53. Bogatcheva E, Hanrahan C, Chen P et al. Discovery of dipiperidines as new antitubercular agents. Bioorg. Med. Chem. Lett. 20(1), 201-205 (2010).
54. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56(5), 968-974 (2005). (Pubitemid 41631930)
55. Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M. Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J. Pharm. Biomed. Anal. 37(4), 793-799 (2005). (Pubitemid 40417755)
56. Nikonenko BV, Samala R, Einck L, Nacy CA. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48(12), 4550-4555 (2004). (Pubitemid 39577652)
57. Onajole OK, Sosibo S, Govender P et al. Novel linear diamine disubstituted polycyclic 'cage' derivatives as potential antimycobacterial candidates. Chem. Biol. Drug Des. 78(6), 1022-1030 (2011).
58. Onajole OK, Govender P, Van Helden PD et al. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur. J. Med. Chem. 45(5), 2075-2079 (2010).
59. Meng Q, Luo H, Chen Y, Wang T, Yao Q. Synthesis of novel [1,2]-diamines with antituberculosis activity. Bioorg. Med. Chem. Lett. 19(18), 5372-5375 (2009).
60. Jia L, Tomaszewski JE, Hanrahan C et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144(1), 80-87 (2005). (Pubitemid 40192564)
61. Armstrong JA, Hart PD. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134(3 Pt 1), 713-740 (1971).
62. Yendapally R, Lee RE. Design, synthesis, and evaluation of novel ethambutol analogues. Bioorg. Med. Chem. Lett. 18(5), 1607-1611 (2008). (Pubitemid 351318253)
63. Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: Literature review and recommendations. Int. J. Tuberc. Lung Dis. 10(12), 1318-1330 (2006). (Pubitemid 44929444)
64. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE 3rd. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action. J. Biol. Chem. 279(38), 40174-40184 (2004). (Pubitemid 39258293)
65. Jia L, Coward L, Gorman GS, Noker PE, Tomaszewski JE. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N- (2-adamantyl)ethane-1,2- diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J. Pharmacol. Exp. Ther. 315(2), 905-911 (2005). (Pubitemid 41500757)
66. Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53(10), 4138-4146 (2009).
67. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33(9), 1493-1499 (1989). (Pubitemid 19228001)
68. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother. 58(2), 332-337 (2006). (Pubitemid 44294944)
69. Van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182(5), 684-692 (2010).
70. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43(5), 615-623 (1999). (Pubitemid 29231686)
71. Langdon G, Wilkins JJ, Smith PJ, McIlleron H. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 8(7), 862-867 (2004). (Pubitemid 38937603)
72. Reddy VM, Dubuisson T, Einck L et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J. Antimicrob. Chemother. 67(5), 1163-1166 (2012).
73. Wallis RS, Jakubiec W, Mitton-Fry M et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU- 100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 7(1), e30479 (2012).
74. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54(7), 2840-2846 (2010).
75. Meng Q, Luo H, Liu Y, Li W, Zhang W, Yao Q. Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents. Bioorg. Med. Chem. Lett. 19(10), 2808-2810 (2009).
76. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother. 51(4), 1563-1565 (2007). (Pubitemid 46586854)
77. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br. J. Pharmacol. 147(5), 476-485 (2006). (Pubitemid 43355045)
78. Sreevatsan S, Stockbauer KE, Pan X et al. Ethambutol resistance in Mycobacterium tuberculosis: Critical role of embB mutations. Antimicrob. Agents Chemother. 41(8), 1677-1681 (1997). (Pubitemid 27339866)
79. Plinke C, Cox HS, Zarkua N et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J. Antimicrob. Chemother. 65(7), 1359-1367 (2010).
80. Belanger AE, Besra GS, Ford ME et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl Acad. Sci. USA 93(21), 11919-11924 (1996).(Pubitemid 26347224)